- Home
- EYEN vs CGTX Comparison
EYEN vs CGTX Comparison
Compare EYEN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- CGTX
- Stock Information
- Founded
- EYEN 2014
- CGTX 2007
- Country
- EYEN United States
- CGTX United States
- Employees
- EYEN N/A
- CGTX N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- EYEN Health Care
- CGTX Health Care
- Exchange
- EYEN Nasdaq
- CGTX Nasdaq
- Market Cap
- EYEN 2.9M
- CGTX 20.5M
- IPO Year
- EYEN 2018
- CGTX 2021
- Fundamental
- Price
- EYEN N/A
- CGTX $0.53
- Analyst Decision
- EYEN Hold
- CGTX Strong Buy
- Analyst Count
- EYEN 4
- CGTX 5
- Target Price
- EYEN $2.00
- CGTX $5.63
- AVG Volume (30 Days)
- EYEN 9.4M
- CGTX 1.9M
- Earning Date
- EYEN 08-11-2025
- CGTX 08-07-2025
- Dividend Yield
- EYEN N/A
- CGTX N/A
- EPS Growth
- EYEN N/A
- CGTX N/A
- EPS
- EYEN N/A
- CGTX N/A
- Revenue
- EYEN $67,063.00
- CGTX N/A
- Revenue This Year
- EYEN $7,680.45
- CGTX N/A
- Revenue Next Year
- EYEN $315.38
- CGTX N/A
- P/E Ratio
- EYEN N/A
- CGTX N/A
- Revenue Growth
- EYEN 663.82
- CGTX N/A
- 52 Week Low
- EYEN $0.85
- CGTX $0.22
- 52 Week High
- EYEN $124.80
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- EYEN 71.65
- CGTX 67.18
- Support Level
- EYEN $7.50
- CGTX $0.29
- Resistance Level
- EYEN $17.18
- CGTX $0.34
- Average True Range (ATR)
- EYEN 3.10
- CGTX 0.03
- MACD
- EYEN 0.88
- CGTX 0.01
- Stochastic Oscillator
- EYEN 81.29
- CGTX 92.26
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.